Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
|ClinicalTrials.gov Identifier: NCT00002080|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin.
Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or < 200.
|Condition or disease||Intervention/treatment||Phase|
|Mycobacterium Avium-intracellulare Infection HIV Infections||Drug: Rifabutin||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002080
|United States, Pennsylvania|
|Saint Davids, Pennsylvania, United States, 19087|